{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Wysdom Radio™","title":"48 Hours to Failure: Anticoagulants and Portal Vein Stents","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/f4c21249\"></iframe>","width":"100%","height":180,"duration":1216,"description":"This episode breaks down a 2026 JVIR retrospective study from the Mayo Clinic (Bretzman et al.), examining portal vein stent outcomes in 182 pancreatic cancer patients, and why the usual fixes for early stent failure may be missing the real cause. At the end, Dr. Rusty Hofmann from Stanford University adds his commentary on the paper.\nThe Surprise on Hardware: Covered vs. bare metal stents showed no significant patency difference, and residual stenosis over 30% didn't predict failure either. This runs counter to standard mechanical assumptions.\nFast, Not Slow, Failure: With 74.6% patency at one year, the stents that do fail occlude fast, a median of just 2 days, pointing to acute thrombosis rather than gradual tumor ingrowth.\nThe Real Driver: The strongest predictors were pre-existing portal occlusion, periportal inflammation, and robust collaterals, evidence for \"immunothrombosis,\" where tumor-driven inflammation triggers clotting at the stent itself.\nThe Anticoagulation Question: Despite 74.7% of patients on anticoagulation, it showed no significant patency benefit, though study limitations leave room for debate.\nDr. Hofmann's Take: He pushes back in his closing commentary, arguing that dosing and drug choice matter more than the paper suggests, and that tissue factor from direct tumor invasion, not anticoagulation intensity, is the real culprit.\nTune in to find out whether it's the blood thinner or the biology calling the shots.\nThis podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.\nBretzman J, Andrews J, Ge S, Kassmeyer B, Fleming C. Portal vein stent placement in a pancreatic cancer cohort: outcomes and predictors of portal stent occlusion. J Vasc Interv Radiol. 2026;37(8):108852. doi:10.1016/j.jvir.2026.108852.","thumbnail_url":"https://img.transistorcdn.com/MTWsVlQNVWnqK7R-Z-jI7G_aa5KttFr_japy-P3mayc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81ODli/OTVlYjRiZjJlZGZi/ZDQxYmE2NDU2YmUx/Y2ZhMy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}